241 related articles for article (PubMed ID: 22760005)
1. A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease.
Sands BE; Katz S; Wolf DC; Feagan BG; Wang T; Gustofson LM; Wong C; Vandervoort MK; Hanauer S
Gut; 2013 Sep; 62(9):1288-94. PubMed ID: 22760005
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis.
Sands BE; Sandborn WJ; Feagan B; Löfberg R; Hibi T; Wang T; Gustofson LM; Wong CJ; Vandervoort MK; Hanauer S;
Gastroenterology; 2008 Aug; 135(2):400-9. PubMed ID: 18602921
[TBL] [Abstract][Full Text] [Related]
3. Immunoregulatory effects of adsorptive granulocyte and monocyte apheresis in patients with drug refractory Crohn's disease.
Nagase K; Fukunaga K; Kashiwamura S; Kono T; Kamikozuru K; Yokoyama Y; Hida N; Ohda Y; Takeda N; Yoshida K; Iimuro M; Kikuyama R; Kato K; Miwa H; Matsumoto T
Ther Apher Dial; 2011 Aug; 15(4):367-73. PubMed ID: 21884471
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of granulocyte and monocyte adsorption apheresis in paediatric inflammatory bowel disease: a prospective pilot study.
Martín de Carpi J; Vilar P; Prieto G; García Novo MD; Ribes C; Varea V
J Pediatr Gastroenterol Nutr; 2008 Apr; 46(4):386-91. PubMed ID: 18367949
[TBL] [Abstract][Full Text] [Related]
5. Adsorptive granulocyte and monocyte apheresis for refractory Crohn's disease: an open multicenter prospective study.
Fukuda Y; Matsui T; Suzuki Y; Kanke K; Matsumoto T; Takazoe M; Matsumoto T; Motoya S; Honma T; Sawada K; Yao T; Shimoyama T; Hibi T
J Gastroenterol; 2004 Dec; 39(12):1158-64. PubMed ID: 15622479
[TBL] [Abstract][Full Text] [Related]
6. The Italian Registry of Therapeutic Apheresis: granulocyte-monocyte apheresis in the treatment of inflammatory bowel disease. A multicentric study.
Passalacqua S; Ferraro PM; Bresci G; D'Ovidio V; Astegiano M; Principi M; Testa R; D'Incà R; Valpiani D; Armuzzi A; Sablich R; Cavallaro F; Costa F; Di Leo V; Colombo E; Santini A; Aratari A; Lecis P; Saladino V; Riegler G; Marco M; Calella F; Ricci C; Guidi ML; Repaci G; Silla M
J Clin Apher; 2011 Dec; 26(6):332-7. PubMed ID: 22072543
[TBL] [Abstract][Full Text] [Related]
7. An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn's disease.
Yoshimura N; Yokoyama Y; Matsuoka K; Takahashi H; Iwakiri R; Yamamoto T; Nakagawa T; Fukuchi T; Motoya S; Kunisaki R; Kato S; Hirai F; Ishiguro Y; Tanida S; Hiraoka S; Mitsuyama K; Ishihara S; Tanaka S; Otaka M; Osada T; Kagaya T; Suzuki Y; Nakase H; Hanai H; Watanabe K; Kashiwagi N; Hibi T
BMC Gastroenterol; 2015 Nov; 15():163. PubMed ID: 26585569
[TBL] [Abstract][Full Text] [Related]
8. Retrospective Single Center Study of Granulocyte Monocyte Adsorption Apheresis Treatment in Inflammatory Bowel Disease.
Edfors K; Ståhlberg D; Söderman C
Ther Apher Dial; 2016 Feb; 20(1):79-85. PubMed ID: 26841133
[TBL] [Abstract][Full Text] [Related]
9. Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease.
Sands BE; Sandborn WJ; Wolf DC; Katz S; Safdi M; Schwartz DA; Hanauer SB
J Clin Gastroenterol; 2006 Jul; 40(6):482-9. PubMed ID: 16825929
[TBL] [Abstract][Full Text] [Related]
10. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment.
Sakuraba A; Motoya S; Watanabe K; Nishishita M; Kanke K; Matsui T; Suzuki Y; Oshima T; Kunisaki R; Matsumoto T; Hanai H; Fukunaga K; Yoshimura N; Chiba T; Funakoshi S; Aoyama N; Andoh A; Nakase H; Mizuta Y; Suzuki R; Akamatsu T; Iizuka M; Ashida T; Hibi T
Am J Gastroenterol; 2009 Dec; 104(12):2990-5. PubMed ID: 19724269
[TBL] [Abstract][Full Text] [Related]
11. A longitudinal study of FDG-PET in Crohn disease patients receiving granulocyte/monocyte apheresis therapy.
Kuwaki K; Mitsuyama K; Kaida H; Takedatsu H; Yoshioka S; Yamasaki H; Yamauchi R; Fukunaga S; Abe T; Tsuruta O; Torimura T
Cytotherapy; 2016 Feb; 18(2):291-9. PubMed ID: 26700210
[TBL] [Abstract][Full Text] [Related]
12. Combination Therapy With Intensive Granulocyte and Monocyte Adsorptive Apheresis Plus Ustekinumab in Patients With Refractory Crohn's Disease.
Tanida S; Mizoshita T; Ozeki K; Katano T; Tanaka M; Nishie H; Shimura T; Okamoto Y; Kubota E; Kataoka H; Joh T
Ther Apher Dial; 2018 Jun; 22(3):295-300. PubMed ID: 29790276
[TBL] [Abstract][Full Text] [Related]
13. The clinical efficacy and safety of granulocyte and monocyte adsorptive apheresis in patients with Crohn's disease: A multicenter retrospective pilot study.
Ueno N; Saito S; Sato M; Sugiyama Y; Kobayashi Y; Murakami Y; Sugimura K; Sasaki T; Sakatani A; Takahashi K; Tanaka K; Serikawa S; Ando K; Kashima S; Muto M; Inaba Y; Moriichi K; Tanabe H; Okumura T; Fujiya M
Ther Apher Dial; 2024 Jun; 28(3):442-452. PubMed ID: 38168492
[TBL] [Abstract][Full Text] [Related]
14. Sargramostim for active Crohn's disease.
Korzenik JR; Dieckgraefe BK; Valentine JF; Hausman DF; Gilbert MJ;
N Engl J Med; 2005 May; 352(21):2193-201. PubMed ID: 15917384
[TBL] [Abstract][Full Text] [Related]
15. Relevance of the processed blood volume per granulocyte and monocyte apheresis session to its clinical efficacy in patients with ulcerative colitis.
Kikuyama R; Fukunaga K; Kawai M; Yokoyama Y; Kamikozuru K; Hida N; Ohda Y; Takeda N; Yoshida K; Iimuro M; Kato K; Kono T; Nogami K; Nagase K; Nakamura S; Takei Y; Miwa H; Matsumoto T
Ther Apher Dial; 2011 Aug; 15(4):360-6. PubMed ID: 21884470
[TBL] [Abstract][Full Text] [Related]
16. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of granulocyte/monocyte apheresis for moderate to severe Crohn's disease.
Eaden JA; Ford AC
Gut; 2013 Apr; 62(4):653. PubMed ID: 23019179
[No Abstract] [Full Text] [Related]
18. Treatment of refractory Crohn's disease by intensive granulocyte and monocyte adsorption apheresis: a report on two drug refractory cases.
Kato S; Kani K; Takabayashi H; Yamamoto R; Ogawa T; Matsuda A; Yakabi K
Intern Med; 2011; 50(15):1591-3. PubMed ID: 21804287
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic effect of intensive granulocyte and monocyte adsorption apheresis combined with thiopurines for steroid- and biologics-naïve Japanese patients with early-diagnosed Crohn's disease.
Fukuchi T; Nakase H; Ubukata S; Matsuura M; Yoshino T; Toyonaga T; Shimazu K; Koga H; Yamashita H; Ito D; Ashida K
BMC Gastroenterol; 2014 Jul; 13():124. PubMed ID: 25015328
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of intensive granulocyte and monocyte adsorption apheresis in a patient with Crohn's disease complicated by extensive subcutaneous aseptic neutrophilic abscesses.
Kato S; Hosomi E; Amano F; Kobayashi T; Kani K; Yamamoto R; Ogawa T; Matsuda A; Sato Y; Izaki S; Mitarai T; Yakabi K
J Crohns Colitis; 2012 Aug; 6(7):787-91. PubMed ID: 22386738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
